CytoDyn’s Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’

CytoDyn’s CEO Dr. Pourhassan and CMO Dr. Kelly to Appear on DrBeen Webcast Tuesday, September 22, 2020

Annual Meeting of Stockholders

Sep 30, 2020 • 9:30 am PDT

Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’

Oct 6 – Oct 8, 2020